Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Harvard Business School
Express Scripts
AstraZeneca
Mallinckrodt

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for PF-04965842

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for PF-04965842?

PF-04965842 is an investigational drug.

There have been 23 clinical trials for PF-04965842. The most recent clinical trial was a Phase 1 trial, which was initiated on December 7th 2017.

The most common disease conditions in clinical trials are Dermatitis, Atopic, Dermatitis, and Eczema. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are three US patents protecting this investigational drug and fifty-seven international patents.

Recent Clinical Trials for PF-04965842
TitleSponsorPhase
Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy ParticipantsPfizerPhase 1
Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic DermatitisPfizerPhase 2
A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy ParticipantsPfizerPhase 1

See all PF-04965842 clinical trials

Clinical Trial Summary for PF-04965842

Top disease conditions for PF-04965842
Top clinical trial sponsors for PF-04965842

See all PF-04965842 clinical trials

US Patents for PF-04965842

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-04965842   Start Trial Pyrrolo[2,3-D]pyrimidine derivatives Pfizer Inc. (New York, NY)   Start Trial
PF-04965842   Start Trial Pyrrolo[2,3-D]pyrimidine derivatives Pfizer Inc. (New York, NY)   Start Trial
PF-04965842   Start Trial Pyrrolo[2,3-D]pyrimidine derivatives Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-04965842

Drugname Country Document Number Estimated Expiration Related US Patent
PF-04965842 Argentina 094857 2033-02-22   Start Trial
PF-04965842 Australia 2014220357 2033-02-22   Start Trial
PF-04965842 Brazil 112015019634 2033-02-22   Start Trial
PF-04965842 Canada 2900703 2033-02-22   Start Trial
PF-04965842 Chile 2015002303 2033-02-22   Start Trial
PF-04965842 China 105008362 2033-02-22   Start Trial
PF-04965842 China 107089985 2033-02-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Merck
Baxter
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.